NCT03291444 2024-03-15
CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
Zhujiang Hospital
Phase 1 Unknown
Clinical Trials
172 trialsNCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT04090268 2024-01-02
SportTherapy
University of Milano Bicocca
Phase NA Unknown
NCT06177561 2023-12-20
Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT
Ruijin Hospital
Phase NA Unknown
NCT05925660 2023-12-05
MUCOPS
Universitaire Ziekenhuizen KU Leuven
Phase NA Unknown
NCT04663100 2023-12-04
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
University of Tennessee
Phase NA Unknown
NCT04856215 2023-10-03
RITII
Great Ormond Street Hospital for Children NHS Foundation Trust
Phase 2 Unknown
NCT04504526 2023-09-15
Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT05932173 2023-07-11
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1/2 Unknown
NCT05576532 2023-06-28
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT04265963 2023-04-18
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271410 2023-04-18
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04271800 2023-04-18
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT04272125 2023-04-18
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT03846362 2023-03-16
A Prospective Multicenter Clinical Trial of MRD-based Treatment Strategy in Children and Young Adults With AML
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Unknown
NCT05495035 2023-03-02
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Unknown
NCT04688021 2023-02-21
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05672420 2023-01-05
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT05649371 2022-12-14
Multiphasic Prehab Allo-HSCT
University of Calgary
Phase NA Unknown
NCT04100187 2022-12-01
Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia
Kecellitics Biotech Company Ltd
Phase 1 Unknown
NCT05291390 2022-11-29
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Armaceutica, Inc.
Phase 2 Unknown
NCT05519384 2022-11-28
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Unknown
NCT05606588 2022-11-04
PrepAIR
University of Basel
Phase NA Unknown
NCT05227898 2022-10-25
RESTORE
Blue Note Therapeutics
Phase NA Unknown
NCT03825367 2022-10-12
Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Unknown
NCT04033627 2022-09-29
TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia
Shanghai Children's Medical Center
Phase NA Unknown
NCT04684472 2022-09-26
Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies
Sichuan University
Phase 1 Unknown
NCT05480501 2022-07-29
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05212584 2022-07-06
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
iCell Gene Therapeutics
Phase 1 Unknown
NCT05445765 2022-07-06
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
iCell Gene Therapeutics
Phase 1 Unknown
NCT03564470 2022-07-01
Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04632316 2022-06-21
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Glycostem Therapeutics BV
Phase 1/2 Unknown
NCT04709458 2022-05-03
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Taiga Biotechnologies, Inc.
Phase 1 Unknown
NCT05309213 2022-04-04
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT05164042 2021-12-20
CAR-T
Shenzhen University General Hospital
Phase 1/2 Unknown
NCT04722952 2021-12-03
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT04014894 2021-11-12
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1 Unknown
NCT05061147 2021-10-01
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Maxinovel Pty., Ltd.
Phase 1/2 Unknown
NCT03798509 2021-08-31
Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Hrain Biotechnology Co., Ltd.
Phase 1 Unknown
NCT00558519 2021-08-18
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT00651261 2021-08-18
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT03795779 2021-05-19
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT02748850 2021-04-01
DIMATE
Assistance Publique Hopitaux De Marseille
Phase NA Unknown
NCT03262298 2021-02-09
Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT02546739 2021-01-26
Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT03271515 2021-01-20
Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL
Beijing Doing Biomedical Co., Ltd.
Phase 1 Unknown
NCT04439721 2021-01-06
γδT
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04336501 2020-12-17
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase NA Unknown
NCT04636918 2020-11-19
Ikervis
Singapore Eye Research Institute
Phase 4 Unknown
NCT04610125 2020-10-30
Clinical Trial of CAR-T in the Treatment of Relapsed and Refractory Hematopoietic and Lymphoid Tissue Tumors in Children
Hebei Senlang Biotechnology Inc., Ltd.
Phase NA Unknown